Nemolizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nemolizumab" in English language version.

refsWebsite

Global rank English rank

195^th place

302^nd place

2^nd place

2^nd place

4^th place

4^th place

1semanticscholar.org

11^th place

8^th place

low place

low place

doi.org

Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.

pharmabiz.com

"Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.

semanticscholar.org

api.semanticscholar.org

Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3). World Health Organization: 411. 2015.